Cargando…

When does the use of individual patient data in network meta-analysis make a difference? A simulation study

BACKGROUND: The use of individual patient data (IPD) in network meta-analyses (NMA) is rapidly growing. This study aimed to determine, through simulations, the impact of select factors on the validity and precision of NMA estimates when combining IPD and aggregate data (AgD) relative to using AgD on...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanters, Steve, Karim, Mohammad Ehsanul, Thorlund, Kristian, Anis, Aslam, Bansback, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805229/
https://www.ncbi.nlm.nih.gov/pubmed/33435879
http://dx.doi.org/10.1186/s12874-020-01198-2
_version_ 1783636278320824320
author Kanters, Steve
Karim, Mohammad Ehsanul
Thorlund, Kristian
Anis, Aslam
Bansback, Nick
author_facet Kanters, Steve
Karim, Mohammad Ehsanul
Thorlund, Kristian
Anis, Aslam
Bansback, Nick
author_sort Kanters, Steve
collection PubMed
description BACKGROUND: The use of individual patient data (IPD) in network meta-analyses (NMA) is rapidly growing. This study aimed to determine, through simulations, the impact of select factors on the validity and precision of NMA estimates when combining IPD and aggregate data (AgD) relative to using AgD only. METHODS: Three analysis strategies were compared via simulations: 1) AgD NMA without adjustments (AgD-NMA); 2) AgD NMA with meta-regression (AgD-NMA-MR); and 3) IPD-AgD NMA with meta-regression (IPD-NMA). We compared 108 parameter permutations: number of network nodes (3, 5 or 10); proportion of treatment comparisons informed by IPD (low, medium or high); equal size trials (2-armed with 200 patients per arm) or larger IPD trials (500 patients per arm); sparse or well-populated networks; and type of effect-modification (none, constant across treatment comparisons, or exchangeable). Data were generated over 200 simulations for each combination of parameters, each using linear regression with Normal distributions. To assess model performance and estimate validity, the mean squared error (MSE) and bias of treatment-effect and covariate estimates were collected. Standard errors (SE) and percentiles were used to compare estimate precision. RESULTS: Overall, IPD-NMA performed best in terms of validity and precision. The median MSE was lower in the IPD-NMA in 88 of 108 scenarios (similar results otherwise). On average, the IPD-NMA median MSE was 0.54 times the median using AgD-NMA-MR. Similarly, the SEs of the IPD-NMA treatment-effect estimates were 1/5 the size of AgD-NMA-MR SEs. The magnitude of superior validity and precision of using IPD-NMA varied across scenarios and was associated with the amount of IPD. Using IPD in small or sparse networks consistently led to improved validity and precision; however, in large/dense networks IPD tended to have negligible impact if too few IPD were included. Similar results also apply to the meta-regression coefficient estimates. CONCLUSIONS: Our simulation study suggests that the use of IPD in NMA will considerably improve the validity and precision of estimates of treatment effect and regression coefficients in the most NMA IPD data-scenarios. However, IPD may not add meaningful validity and precision to NMAs of large and dense treatment networks when negligible IPD are used. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-020-01198-2.
format Online
Article
Text
id pubmed-7805229
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78052292021-01-14 When does the use of individual patient data in network meta-analysis make a difference? A simulation study Kanters, Steve Karim, Mohammad Ehsanul Thorlund, Kristian Anis, Aslam Bansback, Nick BMC Med Res Methodol Research Article BACKGROUND: The use of individual patient data (IPD) in network meta-analyses (NMA) is rapidly growing. This study aimed to determine, through simulations, the impact of select factors on the validity and precision of NMA estimates when combining IPD and aggregate data (AgD) relative to using AgD only. METHODS: Three analysis strategies were compared via simulations: 1) AgD NMA without adjustments (AgD-NMA); 2) AgD NMA with meta-regression (AgD-NMA-MR); and 3) IPD-AgD NMA with meta-regression (IPD-NMA). We compared 108 parameter permutations: number of network nodes (3, 5 or 10); proportion of treatment comparisons informed by IPD (low, medium or high); equal size trials (2-armed with 200 patients per arm) or larger IPD trials (500 patients per arm); sparse or well-populated networks; and type of effect-modification (none, constant across treatment comparisons, or exchangeable). Data were generated over 200 simulations for each combination of parameters, each using linear regression with Normal distributions. To assess model performance and estimate validity, the mean squared error (MSE) and bias of treatment-effect and covariate estimates were collected. Standard errors (SE) and percentiles were used to compare estimate precision. RESULTS: Overall, IPD-NMA performed best in terms of validity and precision. The median MSE was lower in the IPD-NMA in 88 of 108 scenarios (similar results otherwise). On average, the IPD-NMA median MSE was 0.54 times the median using AgD-NMA-MR. Similarly, the SEs of the IPD-NMA treatment-effect estimates were 1/5 the size of AgD-NMA-MR SEs. The magnitude of superior validity and precision of using IPD-NMA varied across scenarios and was associated with the amount of IPD. Using IPD in small or sparse networks consistently led to improved validity and precision; however, in large/dense networks IPD tended to have negligible impact if too few IPD were included. Similar results also apply to the meta-regression coefficient estimates. CONCLUSIONS: Our simulation study suggests that the use of IPD in NMA will considerably improve the validity and precision of estimates of treatment effect and regression coefficients in the most NMA IPD data-scenarios. However, IPD may not add meaningful validity and precision to NMAs of large and dense treatment networks when negligible IPD are used. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-020-01198-2. BioMed Central 2021-01-13 /pmc/articles/PMC7805229/ /pubmed/33435879 http://dx.doi.org/10.1186/s12874-020-01198-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Kanters, Steve
Karim, Mohammad Ehsanul
Thorlund, Kristian
Anis, Aslam
Bansback, Nick
When does the use of individual patient data in network meta-analysis make a difference? A simulation study
title When does the use of individual patient data in network meta-analysis make a difference? A simulation study
title_full When does the use of individual patient data in network meta-analysis make a difference? A simulation study
title_fullStr When does the use of individual patient data in network meta-analysis make a difference? A simulation study
title_full_unstemmed When does the use of individual patient data in network meta-analysis make a difference? A simulation study
title_short When does the use of individual patient data in network meta-analysis make a difference? A simulation study
title_sort when does the use of individual patient data in network meta-analysis make a difference? a simulation study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805229/
https://www.ncbi.nlm.nih.gov/pubmed/33435879
http://dx.doi.org/10.1186/s12874-020-01198-2
work_keys_str_mv AT kanterssteve whendoestheuseofindividualpatientdatainnetworkmetaanalysismakeadifferenceasimulationstudy
AT karimmohammadehsanul whendoestheuseofindividualpatientdatainnetworkmetaanalysismakeadifferenceasimulationstudy
AT thorlundkristian whendoestheuseofindividualpatientdatainnetworkmetaanalysismakeadifferenceasimulationstudy
AT anisaslam whendoestheuseofindividualpatientdatainnetworkmetaanalysismakeadifferenceasimulationstudy
AT bansbacknick whendoestheuseofindividualpatientdatainnetworkmetaanalysismakeadifferenceasimulationstudy